Inclusion Criteria:

- Ages 6-18 years

- Must have successfully completed treatment for ALL and are currently 1-year "disease
free" as judged by the investigators.

- Must meet DSM-IV criteria for "ADHD-NOS.( Attachment A) The attention deficit
symptoms have been precipitated by chemotherapy-related neurological injury.
Therefore, the DSM-IV category is ADHD-NOS.

- Must have an Investigator-completed ADHD-RS total and/or subscale score of ≥1.5
standard deviations above age/gender norm.

- Laboratory results, including chemistries, hematology, and urinalysis do not
demonstrate clinically significant abnormalities.

- ECG demonstrates no clinically significant abnormalities

- Educational level and degree of understanding of the patient and their parents permit
suitable communication between the investigators and study coordinators.

- Subjects and parents are judged to be reliable to keep appointments.

- Must be able to swallow tablets.

- Must have demonstrated compliance during their chemotherapy program.

- Must weigh > 20 kg.

Exclusion Criteria:

- Have relapsed or are having re-occurring symptoms/signs of ALL.

- Have had substantial exposure to radiation therapy (>2000: cGy) since high dose
radiation treatment is associated with neurocognitive deficits or be "treatment
resistant" pharmacologically.

- Past exposure to atomoxetine.

- ADHD symptoms or treatment prior to the diagnosis of ALL

- Documented bipolar disorder, psychosis, affective disorder.

- Female subjects who are pregnant or breastfeeding.

- Suicide risk.

- Seizure disorders (except history of febrile seizures).

- Histories of multiple drug allergies.

- Histories of alcohol or substance abuse.

- Prior or current medical conditions that, in the opinion of the investigators, could
be exacerbated by atomoxetine.

- Sympathomimetic overactivity such as catecholamine secreting tumor.

- Use of MAOI medications.

- Have taken psychostimulants one week prior to randomization.

- Current or past history of hypertension.